Don C. Des Jarlais, PhD
CDUHR - Co-Director & Associate Director, Infectious Disease Epidemiology and Social-behavioral Theory Core
NYU School of Global Public Health - Professor
NYU School of Global Public Health - Professor
Email: don.desjarlais@nyu.edu
Education
PhD, Social Psychology, University of Michigan, Ann ArborBA, Behavioral Science, Rice University
Research Interests
Injecting drug use, Epidemiology, HIV, HCV, Research synthesis BIO
For over 30 years Don Des Jarlais has been conducting HIV/AIDS research among persons who inject drugs (PWID). He is PI of the “Risk Factors” study (R01DA003574), which was instrumental in tracking the HIV/AIDS epidemic in New York City. This study has been funded by the National Institute on Drug Abuse since 1983 and is the longest continuously funded study on HIV/AIDS in persons who use drugs. He has conducted HIV/AIDS research nationally (Seattle, CDC CIDUS studies, national syringe exchange survey) and internationally (in over 20 different countries). He has served as a consultant on these issues to the World Health Organization, the National Institutes of Health and the U.S. Centers for Disease Control and Prevention. Projects
Principal Investigator, Risk Factors for AIDS among Persons Who Inject Drugs: HIV and COVID-19. Active
Principal Investigator, Barriers to Reason: Laws Impacting HIV Prevention Efforts among IDUs in the United States. Completed
Principal Investigator, Combined HIV Prevention for PWID and Future Collaborative Research in Vietnam. Completed
Principal Investigator, Combined Prevention to Reduce Initiation Into Injecting Drug Use. Completed
Principal Investigator, DRIVE (Drug Use and Blood-Borne Infections in Vietnam): Combined Prevention and Care to End the HIV Epidemic Among People Who Inject Drugs in Haiphong, Vietnam. Completed
Principal Investigator, Evaluating ART for All HIV Seropositives: Can It Work with the Hardest Cases?. Completed
Principal Investigator, Expanded Syringe Access Program: NY Evaluation (ESAP). Completed
Principal Investigator, HIV Infection in Ethnic Minority IDUs: An International Systematic Review. Completed
Principal Investigator, HIV Transmission among Injecting and Non-Injecting Drug Users in Tallinn, Estonia. Completed
Principal Investigator, Multiple HIV Prevention Packages for IDUs in Estonia. Completed
Principal Investigator, National Study of Syringe Exchange Programs. Completed
Principal Investigator, WHO Survey Coordinating Center, Drug Injecting Study – Phase 2. Completed
Publications
Recent
Bradley H, Luisi N, Carter A..., Hagan H..., Mateu-Gelabert P..., Des Jarlais DC (2025).
Assessing COVID-19 pandemic impacts on the health of PWID using a novel data sharing model
AIDS, 39 (4), 434-447. doi: 10.1097/QAD.0000000000004076. PMCID: PMC11872276.
Assessing COVID-19 pandemic impacts on the health of PWID using a novel data sharing model
AIDS, 39 (4), 434-447. doi: 10.1097/QAD.0000000000004076. PMCID: PMC11872276.
Chung EO, Patel S, Wenger LD, Humphrey JL, Sukasih A, Bluthenthal RN, Tookes HE, Des Jarlais DC, Glick SN, Lakosky PA, Prohaska S, Guzman L, Kral AH, Lambdin BH (2025).
Association of safer smoking supply distribution with participant encounters and naloxone distribution from syringe services programs: Findings from the National Survey of Syringe Services Programs in the United States
Drug and Alcohol Dependence Reports, 14, 100317. doi: 10.1016/j.dadr.2024.100317. PMCID: PMC11773076.
Association of safer smoking supply distribution with participant encounters and naloxone distribution from syringe services programs: Findings from the National Survey of Syringe Services Programs in the United States
Drug and Alcohol Dependence Reports, 14, 100317. doi: 10.1016/j.dadr.2024.100317. PMCID: PMC11773076.
D'Ottavi M, Scialabba I, Huong DT, Giang HT, Khue PM, Vinh VH, Vallo R, Michel L, Rapoud D, Quillet C, Thanh NTT, Bouniol J, Oanh KTH, Feelemyer J, Perre PV, Laureillard D, Des Jarlais D, Nagot N, Moles JP (2025).
High prevalence and incidence of HSV-2 among people who inject drugs in Hai Phong, Vietnam, and risk factors associated with seroconversion
European Journal of Clinical Microbiology and Infectious Diseases [Epub 2025 Feb 22]. doi: 10.1007/s10096-025-05079-8.
High prevalence and incidence of HSV-2 among people who inject drugs in Hai Phong, Vietnam, and risk factors associated with seroconversion
European Journal of Clinical Microbiology and Infectious Diseases [Epub 2025 Feb 22]. doi: 10.1007/s10096-025-05079-8.
Austin EJ, Briggs ES, Corcorran MA, Chen J, Cotta N, Behrends CN, Prohaska SM, Lakosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN (2025).
“New normal:” Opportunities and challenges faced by syringe service programs following the effects of the COVID-19 pandemic
Substance Use and Misuse, 60 (5), 669-676. doi: 10.1080/10826084.2024.2447411. PMCID: PMC11870795.
“New normal:” Opportunities and challenges faced by syringe service programs following the effects of the COVID-19 pandemic
Substance Use and Misuse, 60 (5), 669-676. doi: 10.1080/10826084.2024.2447411. PMCID: PMC11870795.
Luoma JB, Hoffman K, Wilson-Poe AR, Levander XA, Bazinet A, Cook RR, McCarty D, Pertl K, Bielavitz S, Gregoire D, Wolf RC, Des Jarlais DC, Harrison HV, Stauffer CS, Korthuis PT (2025).
Oregon’s emerging psilocybin services workforce: A survey of the first legal psilocybin facilitators and their training programs
Journal of Psychoactive Drugs [Epub 2025 Jan 29]. doi: 10.1080/02791072.2025.2454474.
Oregon’s emerging psilocybin services workforce: A survey of the first legal psilocybin facilitators and their training programs
Journal of Psychoactive Drugs [Epub 2025 Jan 29]. doi: 10.1080/02791072.2025.2454474.
Notable
Ending HIV epidemics among people who inject drugs in LMICs
Lancet, 392 (10149), 714-719. doi: 10.1016/S0140-6736(18)31721-5.
Dr. Des Jarlais' ResearchGate Profile
Selected Press